Benzodiazepines are currently the most commonly prescribed medication for the treatment of anxiety in older adults, although there is a dearth of good-quality data on this subject. The aim of this review was to systematically review studies examining the efficacy and tolerability of benzodiazepines for the treatment of anxiety disorders among older adults.
Methods
The authors conducted a systematic review, searching PubMed, Ovid MEDLINE, Ovid Embase, Web of Science, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials. All searches were limitedto English-language articles. The quality of each study was appraised using criteria developed by the Centre for Evidence-Based Medicine for randomized controlled trials.
Results
A total of 8,785 citations were retrieved and pooled in EndNote and de-duplicated to 3,753. This set was uploaded to Covidence for screening. Two separate screeners (AG and SAF) evaluated the titles, abstracts, and full text of the eligible articles. Five studies met the inclusion criteria. Across all studies, benzodiazepines were associated with decreased anxiety at the end of the study period. The limited tolerability data show mild adverse effects from the benzodiazepines studied. Limitations of the trials included limited data on the long-term use of benzodiazepines for anxiety and a preponderance of trials examining generalized anxiety disorder, with relatively less data on other anxiety disorders.
Conclusions
Benzodiazepines are effective for treating anxiety disorders in late life, at least in the short term, but more data is needed to establish tolerability and their long-term benefits.
Get full access to this article
View all access options for this article.
References
1.
ReynoldsKPietrzakRHEl-GabalawyR. Prevalence of psychiatric disorders in U.S. older adults: findings from a nationally representative survey. World Psychiatry.2015; 14: 74–81.
2.
BryantCJacksonHAmesD.The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord.2008; 109: 233–250.
3.
KirmiziogluYDoganOKuguN. Prevalence of anxiety disorders among elderly people. Int J Geriatr Psychiatry.2009; 24: 1026–1033.
4.
AndreasSSchulzHVolkertJ. Prevalence of mental disorders in elderly people: the European MentDis_ICF65+ study. Br J Psychiatry.2017; 210: 125–131.
5.
RitchieKArteroSBelucheI. Prevalence of DSM-IV psychiatric disorder in the French elderly population. Br J Psychiatry.2004; 184: 147–152.
6.
SunderlandMAndersonTMSachdevPS. Lifetime and current prevalence of common DSM-IV mental disorders, their demographic correlates, and association with service utilisation and disability in older Australian adults. Aust NZ J Psychiatry.2015; 49: 145–155.
7.
GumAMKing-KallimanisBKohnR.Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the national comorbidity survey-replication. Am J Geriatr Psychiatry.2009; 17: 769–781.
8.
LenzeEJMulsantBHShearMK. Comorbidity of depression and anxiety disorders in later life. Depress Anxiety.2001; 14: 86–93.
King-KallimanisBGumAMKohnR.Comorbidity of depressive and anxiety disorders for older Americans in the national comorbidity survey-replication. Am J Geratr Psychiatry.2009; 17: 782–792.
11.
ShorterETyrerP.Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease. BMJ.2003; 327: 158–160.
12.
SchoeversRABeekmanATDeegDJ. Comorbidity and risk-patterns of depression, generalised anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry.2003; 18: 994–1001.
13.
SmalbruggeMPotAMJongenelisK. Prevalence and correlates of anxiety among nursing home patients. J Affect Disord.2005; 88: 145–153.
14.
BryantCMohlmanJGumA. Anxiety disorders in older adults: looking to DSM5 and beyond. Am J Psychiatry.2013; 21: 872–876.
15.
StewartR.Anxiety and dementia: cause or effect?Acta Psychiatr Scand.2019; 139: 3–5.
16.
GulpersBRamakersIHamelR. Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry.2016; 24: 823–842.
17.
GimsonASchlosserMHuntleyJD. Support for midlife anxiety diagnosis as an independent risk factor for dementia: a systematic review. BMJ open.2018; 8: e019399.
18.
SantabarbaraJLipnickiDMVillagrasaB. Anxiety and risk of dementia: systematic review and meta-analysis of prospective cohort studies. Maturitas.2019; 119: 14–20.
19.
BeaudreauSAO'HaraR.Late-life anxiety and cognitive impairment: a review. Am J Geriatr Psychiatry.2008; 16: 790–803.
20.
GWS. Recognizing and treating anxiety in the elderly. J Clin Psychiatry.1997; 58: 41–47.
21.
FuentesKCoxBJ. Prevalence of anxiety disorders in elderly adults: a critical analysis. J Behav Ther Exp Psychiatry.1997; 28: 269–279.
22.
PalmerBWJesteDVSheikhJI. Anxiety disorders in the elderly: DSM-IV and other barriers to diagnosis and treatment. J Affect Disord.1997; 46: 183–190.
23.
PorenskyEKDewMAKarpJF. The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry.2009; 17: 473–482.
24.
de BeursE, BeekmanAT, van BalkomAJ, . Consequences of anxiety in older persons: its effect on disability, well-being and use of health services. Psychol Med.1999; 29: 583–593.
25.
El-GabalawyRMackenzieCSShooshtariS. Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry.2011; 33: 556–564.
26.
MartensEJde JongeP, NaB, . Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Gen Psychiatry.2010; 67: 750–758.
27.
BargerSDSydemanSJ. Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder?J Affect Disord.2005; 88: 87–91.
28.
ParkerGBOwenCABrotchieHL. The impact of differing anxiety disorders on outcome following an acute coronary syndrome: time to start worrying?Depress Anxiety.2010; 27: 302–309.
29.
BeaudreauSAO'HaraR.Late-life anxiety and cognitive impairment: a review. Am J Geriatr Psychiatry.2008; 16: 790–803.
30.
McClive-ReedKPGellisZD. Anxiety and related symptoms in older persons with dementia: directions for practice. J Gerontol Soc Work.2011; 54: 6–28.
31.
NevilleCTeriL.Anxiety, anxiety symptoms, and associations among older people with dementia in assisted-living facilities. Int J Ment Health Nurs.2011; 20: 195–201.
32.
GallacherJBayerAFishM. Does anxiety affect risk of dementia? Findings from the Caerphilly Prospective Study. Psychosom Med.2009; 71: 659–666.
33.
MohlmanJBCLenzeEJStanleyMAetal.Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry.2012; 27: 549–556.
34.
SachdevPSMohanATaylorL. DSM-5 and mental disorders in older individuals: an overview. Harv Rev Psychiatry.2015; 23: 320–328.
35.
AndreescuCVaronD.New research on anxiety disorders in the elderly and an update on evidence-based treatments. Curr Psychiatry Rep.2015; 17: 53.
SorkinDHMurphyMNguyenH. Barriers to mental health care for an ethnically and racially diverse sample of older adults. J Am Geriatr Soc.2016; 64: 2138–2143.
40.
BrenesGADanhauerSCLylesMF. Barriers to mental health treatment in rural older Adults. Am J Geriatr Psychiatry.2015; 23: 1172–1178.
41.
WuthrichVMFreiJ.Barriers to treatment for older adults seeking psychological therapy. Int Psychogeriatr.2015; 27: 1227–1236.
42.
KishitaNLaidlawK.Cognitive behaviour therapy for generalized anxiety disorder: is CBT equally efficacious in adults of working age and older adults?Clin Psychol Rev.2017; 52: 124–136.
43.
AbejuelaHROsserDN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an algorithm for generalized anxiety disorder. Harv Rev Psychiatry.2016; 24: 243–256.
44.
SchuurmansJComijsHEmmelkampPM. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry.2006; 14: 255–263.
45.
SchuurmansJComijsHEmmelkampPM. Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr.2009; 21: 1148–1159.
46.
HendriksGJKeijsersGPKampmanM. A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand.2010; 122: 11–19.
47.
LenzeEJMulsantBHShearMK. Efficacy and tolerability of Citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry.2005; 162: 146–150.
48.
BlankSLenzeEJMulsantBH. Outcomes of late-life anxiety disorders during 32 weeks of Citalopram treatment. J Clin Psychiatry.2006; 67: 468–472.
49.
LenzeEJRollmanBLShearMK. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA.2009; 301: 295–303.
50.
AlakaKJNobleWMontejoA. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry.2014; 29: 978–986.
51.
DavidsonJAllgulanderCPollackMHetal.Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol.2008; 23: 519–526.
52.
KatzIRReynoldsCF 3rd, AlexopoulosGS, . Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc.2002; 50: 18–25.
53.
SheikhJISwalesPJ. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, Imipramine, and placebo. Int J Psychiatry Med.1999; 29: 107–117.
54.
MokhberNAzarpazhoohMRKhajehdalueeM. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci.2010; 64: 128–133.
55.
BohmCRobinsonDSGammansRE. Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol.1990; 10: 47s–51s.
56.
MontgomerySChatamraKPauerL. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry.2008; 193: 389–394.
FourrierALetenneurLDartiguesJF. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol.2001; 57: 419–425.
59.
JormAFGraysonDCreaseyH. Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health.2000; 24: 7–10.
60.
GerlachLBOlfsonMKalesHC. Opioids and other central nervous system-active polypharmacy in older adults in the United States. J Am Geriatr Soc.2017; 65: 2052-2056.
61.
MaherRLHanlonJHajjarER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf.2014; 13: 57–65.
62.
LenzeEJPollockBGShearMK. Treatment considerations for anxiety in the elderly. CNS spectrums.2003; 8: 6–13.
63.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc.2015; 63: 2227–2246.
64.
Diaz-GutierrezMJMartinez-CengotitabengoaMSaez de AdanaE, . Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas.2017; 101: 17–22.
65.
LabergeSCrizzleAM. A literature review of psychotropic medications and alcohol as risk factors for falls in community dwelling older adults. 2019; 39: 117–139.
66.
BallokovaAPeelNMFialovaD. Use of benzodiazepines and association with falls in older people admitted to hospital: a prospective cohort study. Drugs Aging.2014; 31: 299–310.
67.
WoolcottJCRichardsonKJWiensMO. Metaanalysis of the impact of 9 medication classes on falls in elderly persons. Arch Int Med.2009; 169: 1952–1960.
68.
Billioti de GageS, MorideY, DucruetT, . Benzodiazepine use and risk of Alzheimer's disease: case-controlstudy. BMJ.2014; 349: g5205.
69.
ImfeldPBodmerMJickSS. Benzodiazepine use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis. Drug Saf.2015; 38: 909–919.
70.
BietryFA PAReichOSchwenkglenksM. Benzodiazepine use and risk of developing Alzheimer's disease: a case-control study based on Swiss claims data. CNS Drugs.2017; 31: 245–251.
71.
GraySLDublinSYuO. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ (Clinical research ed). 2016; 352: i90. doi: https://doi.org/10.1136/bmj.i90.
72.
MoriartyFCahirCBennettK. Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models. 2019; 9: e021832.
73.
CohnJB. Double-blind safety and efficacy comparison of alprazolam and placebo in the treatment of anxiety in geriatric patients. Curr Ther Resl.1984; 35: 100–112.
74.
BresolinNMonzaGScarpiniE. Treatment of anxiety with ketazolam in elderly patients. Clin Ther.1988; 10: 536–542.
75.
KoepkeHHGoldRLLindenME. Multicenter controlled study of oxazepam in anxious elderly outpatients. Psychosomatics.1982; 23: 641–645.
76.
LépineJP, BotteL, JourdainG, . Comparison of suriclone and lorazepam in the treatment of generalized anxiety disorders in the elderly. Clin Neuropharmacol.1992; 15: 173B.
77.
FeighnerJP. Ketazolam once-a-day in the treatment of anxiety: a double-blind comparison with diazepam and placebo. Curr Ther Res Clin Exp.1980; 28: 425–431.
78.
AnhaltHSYoungRRoginskyM.Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs T.I.D. dosing. J Clin Psychiatry.1980; 41: 386–392.
